PF-4 Antibody (G-7): sc-374195

PF-4 Antibody (G-7) is a mouse monoclonal IgG1 antibody that detects platelet factor-4 (PF-4) in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). PF-4 is a 70 amino acid protein released from the alpha-granules of activated platelets, playing a crucial role in hemostasis by binding with high affinity to heparin and related sulfated glycosaminoglycans. This interaction neutralizes heparin-like molecules on the endothelial surface of blood vessels, thereby inhibiting antithrombin III activity and promoting coagulation. PF-4 also acts as a potent chemoattractant for neutrophils and fibroblasts, suggesting involvement in inflammatory responses and wound healing processes. Studies have shown that PF-4 expression is significantly elevated in the spleens of adult mice with allergic dermatitis, indicating a potential role in atopic dermatitis pathogenesis. The gene encoding PF-4 is located on human chromosome 4q13.3 and is classified as a small inducible gene, reflecting its size and stimulation during platelet activation. Anti-PF-4 antibody (G-7) serves as an essential tool for researchers investigating PF-4′s multifaceted roles in coagulation and inflammation.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PF-4 Antibody (G-7) References:

1. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact.  |  Van den Steen, PE., et al. 2000. Blood. 96: 2673-81. PMID: 11023497
2. Influence of angiogenesis inhibitors, endostatin and PF-4, on lymphangiogenesis.  |  Shao, XJ. and Xie, FM. 2005. Lymphology. 38: 1-8. PMID: 15856679
3. Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase and cathepsin G.  |  Schiemann, F., et al. 2006. Blood. 107: 2234-42. PMID: 16317101
4. In vivo fate and therapeutic efficacy of PF-4/CTF microspheres in an orthotopic human glioblastoma model.  |  Benny, O., et al. 2008. FASEB J. 22: 488-99. PMID: 17873103
5. Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor.  |  Auerbach, DJ., et al. 2012. Proc Natl Acad Sci U S A. 109: 9569-74. PMID: 22645343
6. PF 4 versus beta TG as evidence for platelet activation in myeloproliferative disorders.  |  Luzzatto, G., et al. 1985. Scand J Haematol. 35: 299-304. PMID: 2414843
7. Platelet factor 3 (PF 3) and platelet factor 4 (PF 4) as a guide to platelet membrane structure.  |  O'Brien, JR. 1971. Acta Med Scand Suppl. 525: 87-8. PMID: 5292111
8. The influence of a peptide sequence from PF-4 (CT-112) on type II collagen-induced arthritis in mice.  |  Wooley, PH., et al. 1995. Inflamm Res. 44 Suppl 2: S125-6. PMID: 8548360
9. Anti-inflammatory activity of an orally active peptide sequence from PF-4 on acute inflammation and DTH.  |  Talmadge, JE., et al. 1995. Inflamm Res. 44 Suppl 2: S199-200. PMID: 8548397
10. TNF-alpha renders human neutrophils responsive to platelet factor 4. Comparison of PF-4 and IL-8 reveals different activity profiles of the two chemokines.  |  Petersen, F., et al. 1996. J Immunol. 156: 1954-62. PMID: 8596050

The preferred PF-4 antibody is PF-4 Antibody (D-7): sc-398979.